Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Journal of Medical Economics|February 21, 2022
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United StatesRaquel Aguiar-Ibáñez, Chloë Hardern, Frank van Hees, et al.
Clinical Colorectal Cancer|July 30, 2014
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancerVan Morris, Michael J Overman, Zhi-Qin Jiang, et al.
Clinical Colorectal Cancer|July 19, 2020
Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced HypersplenismAlexandre A Jácome, Aki Ohinata, Armeen Mahvash, et al.
Cancer Chemotherapy and Pharmacology|April 12, 2011
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trialDavid Fogelman, Mehrdad Jafari, Gauri R Varadhachary, et al.
The American Journal of Dermatopathology|April 5, 2016
Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported CasePrasamsa Pandey, Rami N Al-Rohil, Jennifer B Goldstein, et al.
Cancer Medicine|April 30, 2019
Association between frailty syndrome and survival in patients with pancreatic adenocarcinomaAn Ngo-Huang, Holly M Holmes, Jude K A des Bordes, et al.
The American Journal of Bioethics : AJOB|May 23, 2025
Growth Attenuation Therapy: Ongoing Ethical and Practical Challenges 20 Years Post AshleyStephen D Brown, Kerri O Kennedy, Faye F Holder-Niles, et al.
Langenbeck'S Archives of Surgery|July 16, 2017
Home-based exercise during preoperative therapy for pancreatic cancerAn Ngo-Huang, Nathan H Parker, Xuemei Wang, et al.
Pageof 6